Biocon Ltd. reported a 95% fall in net profit for the first quarter of financial year 2026.
The pharma company reported a consolidated bottom line of Rs 31.4 crore, a sharp fall from net profit of Rs 659.70 crore in the year-ago period.
Biocon Q1 Highlights (Consolidated, YoY)
Revenue up 14.8% to Rs 3,941.90 crore versus Rs 3,432.90 crore.
Net profit down 95% to Rs 31.40 crore versus Rs 659.70 crore.
Ebitda up 21% to Rs 748.90 crore versus Rs 620.40 crore.
Margin at 19% versus 18.1%
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
